OrthoTrophix Announces Early Completion of Enrollment in Phase 2b Trial of TPX-100 in Knee Osteoarthritis
PR Newswire —
FOSTER CITY, Calif., Feb. 24, 2026 /PRNewswire/ -- OrthoTrophix, Inc., a privately held biopharmaceutical company developing novel investigational therapies for osteoarthritis, today announced the early completion of the planned patient enrollment in its Phase 2b clinical trial evaluating...